PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

3 Feb 2021 07:00

RNS Number : 7080N
Hutchison China Meditech Limited
03 February 2021
 

Chi-Med to Announce 2020 Final Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, February 3, 2021: Hutchison China MediTech Limited (¡§Chi-Med¡¨) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST).

 

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.

 

The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

 

 

About Chi-Med

 

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries

 

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

 

 

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

 

 

Nominated Advisor

 

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORDZGGZLZNGMZG
Date   Source Headline
31st May 20167:00 amRNSTotal Voting Rights
13th May 20167:00 amRNSEnrollment completion of Phase III fruquintinib
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20161:12 pmRNSResults of Annual General Meeting
13th Apr 20164:23 pmRNSExercise of Overallotment Option
31st Mar 20167:00 amRNSTotal Voting Rights
29th Mar 20168:00 amRNSDirector/PDMR Shareholding
23rd Mar 201610:34 amRNSHolding(s) in Company
22nd Mar 20162:00 pmRNSClosing of U.S. Public Offering of ADSs
21st Mar 20168:54 amRNSDirector/PDMR Shareholding
21st Mar 20167:00 amRNSSulfatinib Phase III registration study
18th Mar 20164:18 pmRNSFinal Prospectus
17th Mar 20167:00 amRNSPricing of U.S. Public Offering of ADSs
15th Mar 20167:00 amRNS2015 Annual Report and Notice of AGM
7th Mar 20167:59 amRNSFifth Filing of Form F-1 Registration Statement
4th Mar 20166:12 pmRNSLaunch of Potential U.S. Public Offering of ADSs
4th Mar 20165:54 pmRNSFifth Filing of Form F-1 Registration Statement
2nd Mar 20167:00 amRNSSulfatinib Phase II initation in thyroid cancer
1st Mar 20164:29 pmRNSFourth Filing of Form F-1 Registration Statement
1st Mar 20167:00 amRNSFinal Results
11th Feb 20165:39 pmRNSPublic Filing of Form F-1 Registration Statement
29th Jan 20168:03 amRNSNotice of Results
15th Jan 20167:02 amRNSChi-Med initiates HMPL-523 Phase I clinical trial
29th Dec 20157:43 amRNSBlocklisting Six Monthly Return
18th Dec 20157:00 amRNSInitiation sulfatinib Phase III registration study
9th Dec 20157:00 amRNSUS$105 m Shanghai land compensation agreement
8th Dec 20157:00 amRNSInitiation of fruquintinib Phase 3 trial in NSCLC
13th Nov 20152:50 pmRNSSecond Public Filing of Registration Statement
10th Nov 20151:13 pmRNSResults of Extraordinary General Meeting
9th Nov 20157:59 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSChi-Med initiates sulfatinib U.S. clinical trials
30th Oct 20157:00 amRNSClinical results presented
30th Oct 20157:00 amRNSTotal Voting Rights
30th Oct 20157:00 amRNSCompletion of Phase I clinical trial of HMPL 523
20th Oct 20152:40 pmRNSDirector's Share Dealing
19th Oct 20157:00 amRNSAwards under Long Term Incentive Plan
16th Oct 201512:17 pmRNSShareholders' Circular and Notice of EGM
16th Oct 201512:15 pmRNSFiling of Registration Statement on Form F1
16th Oct 201512:03 pmRNSChi-Med files Nasdaq Registration Statement
13th Oct 20157:00 amRNSEnrolment complete in Savolitinib Phase II trial
12th Oct 20152:09 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSPresentation at 2015 European Cancer Congress
2nd Sep 201511:57 amRNSTrial of fruquintinib achieves primary endpoint
19th Aug 201512:14 pmRNSTermination of R&D agreement with Janssen
28th Jul 20157:00 amRNSInterim Results
23rd Jul 20151:05 pmRNSNotification of major interest in shares
23rd Jul 20151:01 pmRNSNotification of major interest in shares
23rd Jul 20159:01 amRNSMitsui exchanges shares in Hutchison MediPharma
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.